TTE - Unfortunately, your NWBO experience was poorly timed. You should know by now biotech stock ownership is often a marathon riddled with volatility. You must have suffered through the Woodford fund meltdown and AF's targeted bear campaigns. The same crap happened with Amrn, which allowed me to pick up shares @ avg 1.54 in late 2016. I had the same good fortune to buy NWBO @$.18 .$.19 with an avg $.47
When I bought into both stocks that year, my broker sounded like you. "These are cult stocks, and known for being heavily shorted." Jelis and many articles supported my reasoning for going big on Amrn in 2016, NWBO had even more tea leaves pointing to success, more than I would have imagined possible without actually having inside information to trade on.
But when you owned NWBO, immunotherapy was still in its infancy. The trial design turned out to be poorly suited for immunotherapy, because of Pseudo progression false flags, and insufficient imaging technology, which made discernment even more difficult. So while AF and the bears took advantage, like a BOSS, LP persevered. The regulators told NWBO that it was unethical not to allow cross over, because at some point the company saw people on treatment were living longer. That made PFS problematic. So the best thing to do to overcome the shortcoming was to go a full five years to allow the KM curve to show meaningful separation. Your comment implies that LP did things in a whim, which is completely false. NWBO has always worked closely with regulators and statisticians to proceed in the best way possible, so as not to jeopardize all the blood, sweat, and tears that went into running a huge logistics behemoth. YESTERDAY'S Jama was vindication and a victory lap. She's also said for several years, that having the product without manufacturing ready is not enough. She destroyed that concern through her genius purchase of Flashworks in 2020 for a steal of $5 million.
So your expectations were misguided given the evolving understanding and regulatory expectations as time progressed. You can't just point to the CEO and claim it's all her fault, because it didn't happen fast enough. I'm in for almost 8 years. I've slept like a baby, because I've adapted my expectations to meet the circumstances. It's not complicated to understand imo.
As for Amrn, I was way too naive about the legal system. But the ROW exclusivity gave me some confidence that the money I invested @ $19.70 in a separate account, would at some point break even. Ironically, Amrn's demise provided me with an unimaginable opportunity to move Amrn profits to owning massive NWBO shares at a ridiculous low avg cost. Did you know that NWBO was going to do a combo trial with BMY at UCLA, and then all of a sudden it changed to Keytruda and DCVAX? That's a major coup. I don't know what, how, why, but Merck must have been hot and heavy.
I think we see a BO soon, or a Partnership.
ILT
AI
Market Data 
Markets 
